Clinical Trial

Bispecific CD19/CD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
To determine the safety, toxicity, and maximum tolerated dose (MTD) of CD19/CD20 bispecific CAR-T cells with 4-1BB and mutated CD28 costimulatory domains (20-19 Tan BB06z) in patients with relapsed or refractory CD19+ aggressive hematologic malignancies
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-07-08.
Trial Details
NCT Number NCT07701889
Lead Sponsor Roswell Park Cancer Institute
Conditions Hematologic Diseases
Enrollment 21 participants
Start Date 2026-10
Primary Completion 2028-10 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-15